WP
Woodline Partners Portfolio holdings
AUM
$18.9B
1-Year Return
23.37%
This Quarter Return
+9.42%
1 Year Return
+23.37%
3 Year Return
+125.78%
5 Year Return
+185.63%
10 Year Return
–
AUM
$11.8B
AUM Growth
+$1.41B
(+13%)
Cap. Flow
+$896M
Cap. Flow
% of AUM
7.57%
Top 10 Holdings %
Top 10 Hldgs %
12.15%
Holding
744
New
202
Increased
220
Reduced
152
Closed
160
Top Buys
| 1 |
ASML
ASML
|
$125M |
| 2 |
Meta Platforms (Facebook)
META
|
$100M |
| 3 |
STMicroelectronics
STM
|
$92.5M |
| 4 |
MetLife
MET
|
$79.4M |
| 5 |
Gilead Sciences
GILD
|
$77.3M |
Top Sells
| 1 |
TE Connectivity
TEL
|
$161M |
| 2 |
Eli Lilly
LLY
|
$151M |
| 3 |
Marsh & McLennan
MMC
|
$123M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
$86.7M |
| 5 |
Electronic Arts
EA
|
$78.6M |
Sector Composition
| 1 | Healthcare | 43.57% |
| 2 | Technology | 17.47% |
| 3 | Industrials | 8.1% |
| 4 | Energy | 6.42% |
| 5 | Financials | 6.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
326
Akero Therapeutics
AKRO
$3.58B
| $8.39M | 0.07% |
292,468
+92,036
| +46% | +$2.64M |
|
327
Core & Main
CNM
$12.7B
| $8.37M | 0.07% |
188,476
-46,683
| -20% | -$2.07M |
|
|
CNTA
328
Centessa Pharmaceuticals
CNTA
$2.11B
| $8.26M | 0.07% |
516,379
+392,918
| +318% | +$6.28M |
|
329
Larimar Therapeutics
LRMR
$337M
| $8.15M | 0.07% |
1,244,551
+1,966
| +0.2% | +$12.9K |
|
330
Absci
ABSI
$368M
| $7.99M | 0.07% |
2,090,801
+615,725
| +42% | +$2.35M |
|
331
Pultegroup
PHM
$27.7B
| $7.93M | 0.07% |
+55,219
| New | +$7.93M |
|
|
STKL
332
SunOpta
STKL
$779M
| $7.79M | 0.07% |
1,220,735
-1,554,090
| -56% | -$9.92M |
|
333
Spyre Therapeutics
SYRE
$1.03B
| $7.77M | 0.07% |
264,256
+1,640
| +0.6% | +$48.2K |
|
334
Lexeo Therapeutics
LXEO
$271M
| $7.7M | 0.06% |
851,961
+27,887
| +3% | +$252K |
|
335
Nurix Therapeutics
NRIX
$758M
| $7.57M | 0.06% |
336,879
+34,992
| +12% | +$786K |
|
336
Rhythm Pharmaceuticals
RYTM
$6.78B
| $7.53M | 0.06% |
143,823
+99,576
| +225% | +$5.22M |
|
|
SLN
337
Silence Therapeutics
SLN
$269M
| $7.4M | 0.06% |
406,903
+316,041
| +348% | +$5.75M |
|
338
Cognex
CGNX
$7.55B
| $7.34M | 0.06% |
+181,255
| New | +$7.34M |
|
339
GoodRx Holdings
GDRX
$1.39B
| $7.29M | 0.06% |
1,050,994
+1,006,339
| +2,254% | +$6.98M |
|
340
Diamondback Energy
FANG
$40.2B
| $7.23M | 0.06% |
+41,909
| New | +$7.23M |
|
341
Delta Air Lines
DAL
$39.9B
| $7.21M | 0.06% |
141,860
+7,579
| +6% | +$385K |
|
342
Taylor Morrison
TMHC
$7.1B
| $7.12M | 0.06% |
+101,313
| New | +$7.12M |
|
|
BCAX
343
Bicara Therapeutics Inc. Common Stock
BCAX
$658M
| $7.08M | 0.06% |
+277,969
| New | +$7.08M |
|
344
KalVista Pharmaceuticals
KALV
$796M
| $7.04M | 0.06% |
608,253
+457,791
| +304% | +$5.3M |
|
345
Prestige Consumer Healthcare
PBH
$3.2B
| $6.88M | 0.06% |
95,453
+27,405
| +40% | +$1.98M |
|
346
Dianthus Therapeutics
DNTH
$853M
| $6.86M | 0.06% |
250,504
+171
| +0.1% | +$4.68K |
|
347
Cytokinetics
CYTK
$6.34B
| $6.81M | 0.06% |
129,035
-69,146
| -35% | -$3.65M |
|
348
Rapid7
RPD
$1.32B
| $6.81M | 0.06% |
170,644
+13,919
| +9% | +$555K |
|
349
GE HealthCare
GEHC
$34.6B
| $6.73M | 0.06% |
71,669
-3,331
| -4% | -$313K |
|
350
TEGNA Inc
TGNA
$3.38B
| $6.71M | 0.06% |
+425,330
| New | +$6.71M |
|